Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

DeepHealth is introducing in Europe its cloud-first integrated portfolio combining clinical AI, multi-modality viewing and reporting, which is designed to improve outcomes, efficiency and access to ca ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists ...

Recognising these subtle body changes can lead to an earlier diagnosis, when treatment is more likely to be successful ...

EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026Company to host conference call and webcast on Wednesday, ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

After learning that they carry a mutated version of the BRCA1 gene, their options were to undergo intensive monitoring every six months or to have preventive surgeries involving profound changes to th ...

The disease entered Linda Adhiambo’s family in 2007 and never left. It has taken her mother, grandmother, aunt and cousins. Now, as she battles breast cancer, she asks: when will this cycle end?

According to a company press release, RadNet, Inc. has acquired Gleamer SAS, a leading radiology AI company based in Paris, France. The acquisition will be integrated into DeepHealth, RadNet’s wholly ...